This site uses cookies to store information on your computer. Learn more x

DSM Biomedical proprietary polymers help customers, AxioMed and Sunshine Heart, reach commercial and clinical success

Berkeley CA, US, 02 Jun 2009 13:00 CEST

DSM Biomedical, a global company serving the medtech and biotech industries and part of Royal DSM N.V., announces two customers, AxioMed Spine and Sunshine Heart, are celebrating commercial and clinical success of their medical devices made with proprietary DSM Biomedical polymers.

AxioMed® Spine Corp. has recently received CE Mark approval for its Freedom® Lumbar Disc, an elastomeric total spinal disc replacement device. The CE Mark clears AxioMed to introduce the medical device into the European Union market. Using a patented silicone-urethane copolymer under exclusive license from DSM Biomedical, AxioMed's lumbar disc is designed to replicate the natural function of a human disc. The Freedom Lumbar Disc was developed and designed by AxioMed clinicians and experts in the fields of biomechanics, pathology, and spine surgery in combination with DSM Biomedical experts in polymer science and processing. The material characteristics of DSM Biomedical's polymer, in combination with AxioMed's implant design, provides three-dimensional motion that mimics the natural biomechanics of the spine.

We believe our Freedom disc may represent the next generation of technology for treating degenerative disc disease,” said Patrick McBrayer, AxioMed's President and CEO. “The goal of our technology is to restore the natural function of the spine. DSM Biomedical's polymer is well-suited to this goal. Its viscoelastic properties allow for compression, rotation and translation, while simultaneously providing load transfer and damping.

Sunshine Heart Inc. recently announced that The Ohio State University Medical Center has successfully completed the first two implants of the Company's C-Pulse™ heart assist system under a 20-person clinical trial approved by the FDA. C-Pulse is designed as a non-blood contacting heart assist therapy for treating patients with moderate to severe heart failure, a condition in which the heart progressively loses its ability to efficiently pump blood throughout the body. The C-Pulse device, which must pulsate up to 750,000 times per week, is made with two DSM Biomedical polymers.

We started working with DSM Biomedical on an exploratory development program, advanced to a manufacturing program, and in result have developed a very durable Cuff for the C-Pulse,” said Donald Rohrbaugh, CEO of Sunshine Heart. “We are very pleased with the partnership that has developed between Sunshine Heart and DSM Biomedical.

We are very happy to partner with these two emerging medtech companies,” added Bob Ward, President and CEO of DSM PTG, a part of DSM Biomedical. “The major milestones achieved by AxioMed Spine and Sunshine Heart occur within one year of the acquisition of The Polymer Technology Group (PTG) by DSM. Today, the combined resources of the former PTG and DSM ensure continued investment in new technology for delivering biomedical materials that advance or enable the development of next-generation medical devices.